Abstract
The history of breast cancer risk assessment can be traced to the early 1700s when the observation was made in Italy that nuns were more likely to die of breast cancer than the general population. Although nulliparity has since been confirmed as a breast cancer risk factor, quantification of this risk is not as straightforward as it might seem. Risks are present, of course, but unidentified. Additionally, the widespread attention given to risk factors for breast cancer has had the unintended effect of transmitting a false sense of security to eventual breast cancer patients who do not have the publicized risks.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ottman R, Pike MC, King MC, Henerson BE. Practical guide for estimating risk for familial breast cancer. Lancet. 1983;2:556–8.
Anderson DE, Badzioch MD. Risk of familial breast cancer. Cancer. 1985;56:383–7.
Dupont WD. Converting relative risks to absolute risks: a graphical approach. Stat Med. 1989;8:641–51.
Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146–51.
Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.
Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994;73:643–51.
Bodian CA, Perzin KH, Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer. 1996;78:1024–34.
Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111–30. Erratum in: Stat Med. 2005;24(1):156.
Chen J, Pee D, Ayyagari R, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst. 2006;98:1215–26.
Tice JA, Cummings SR, Siv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screened population. Breast Cancer Res Treat. 2005;94:115–22.
Bondy ML, Newman LA. Assessing breast cancer risk: evolution of the Gail model (editorial). J Natl Cancer Inst. 2006;98:1172–3.
Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst. 2010;102:680–91.
Gail MH, Mai PL. Comparing breast cancer risk assessment models. J Natl Cancer Inst. 2010;102:665–8.
Tice JA, Cummings SR, Smith-Bindman R, et al. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med. 2008;148:337–47.
Berry DA, Iversen ES, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20:2701–12.
Freedman AN, Seminara D, Gail MH, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 2005;97:715–23.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.
Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41.
Vogel VG, Costantino JP, Wickerham DL, et al. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project breast cancer chemoprevention trials. J Natl Cancer Inst Monogr. 2010;41:181–6.
Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Eng J Med. 1999;340:77–84.
Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633–7.
Grann VR, Jacobson JS, Thomason D, et al. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA 1/2 mutations; an updated decision analysis. J Clin Oncol. 2002;20:2520–9.
Parmigiani G, Chen S, Iversen ES, et al. Validity of models for predicting BRCA2 and BRCA2 mutations. Ann Intern Med. 2007;147:441–50.
Hollingsworth AB, Singletary SE, Morrow M, et al. Current comprehensive assessment and management of women at increased risk for breast cancer. Am J Surg. 2004;187:349–62.
Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–9.
Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med. 1997;336:611–7.
Gail MH. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J Natl Cancer Inst. 2009;101:959–63.
Wrensch MR, Petrakis NL, Miike R, et al. Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst. 2001;93:1791–8.
Vogel VG, editor. Management of patients at high risk for breast cancer. Malden, MA: Blackwell Science; 2001.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hollingsworth, A.B. (2014). Risk Assessment. In: Francescatti, D., Silverstein, M. (eds) Breast Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8063-1_1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8063-1_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-8062-4
Online ISBN: 978-1-4614-8063-1
eBook Packages: MedicineMedicine (R0)